Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oriola Corporation is a Nordic health and wellbeing company specializing in the wholesale and distribution of pharmaceuticals and health products. It operates primarily in Finland and Sweden, providing pharmaceutical logistics, dose dispensing, research pharmacy services, and advisory support including commercial data, clinical trials, regulatory affairs, and pharmacovigilance. The company distributes a broad range of items such as vitamins, food supplements, sports nutrients, wound care products, beauty items, vaccines, and over-the-counter medicines to pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, retailers, and e-commerce platforms. Oriola Corporation manages segments including Consumer, Pharma, and Retail, with a notable 50% stake in Kronans Apotek, Sweden's third-largest pharmacy chain. Founded in 1907 and headquartered in Espoo, Finland, it employs around 816 professionals and maintains a share capital of EUR 147,899,766.14, with 185,325,378 shares registered. Oriola Corporation plays a vital role in ensuring reliable supply chains and enhancing pharmaceutical care safety across the Nordic region, classified under Health Care Distributors.
€0.94
+€0.03 (+3.07%)
EOD Jul 2, 2026
Operating margin is thin at 0.13%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 13.5%, still solid.
ROIC dropped from 5.09% to 1.04%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.91B
▲ +13.5% YoY
Net Income (TTM)
-€24M
▼ -35.3% YoY
Op. Margin
0.38%
▼ -0.7pp YoY
ROIC
1.04%
▼ -4.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€4M
▲ +57.9% YoY
Op. Cash Flow (TTM)
€30M
▲ +55.0% YoY
Net Debt
-€82M
Net Cash Position
Cash & Equiv.
€152M
Continue Research
Oriola (ORIOLA.XHEL) trades above a two-stage DCF intrinsic value of about €0.77 per share, so at €0.94 the stock looks overvalued (18.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oriola scores 37/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 7.3%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €0.77 per share for ORIOLA.XHEL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €0.58. At today's €0.94, that puts the stock about 18.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Oriola scores 37 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 0.4% operating margin and a 1.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Oriola pays a regular dividend of about €0.07 per share per year (typically in quarterly installments), a yield of roughly 7.3% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ORIOLA.XHEL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ORIOLA.XHEL currently trades above its estimated intrinsic value and scores 37/100 on quality (lower-quality). It also yields about 7.3%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.